A sensitive Tg assay or rhTSH stimulated Tg: What's the best in the long-term follow-up of patients with differentiated thyroid carcinoma?

PLoS ONE

Volumn 2, Issue 8, 2007, Pages

  Persoon, Adrienne C M ^a   Jager, Pieter L ^a   Sluiter, Wim J ^a   Plukker, John T M ^a   Wolffenbuttel, Bruce H R ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NECK ECHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RADIOIMMUNOASSAY; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING; BIOASSAY; BLOOD; CARCINOMA; EVALUATION; MIDDLE AGED; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; BIOLOGICAL ASSAY; CARCINOMA; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 41049092326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000816     Document Type: Article

References (34)

1. Mazzaferri EL, Kloos RT (2001) Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid carcinoma. J Clin Endocrinol Metab 86: 1447-1463.
2. Lo Gerfo P, Colacchio TA, Colacchio DA, Feind CR (1980) Effect of TSH stimulation on serum thyroglobulin in metastatic thyroid carcinoma. J Surg Oncol 14: 195-200.
3. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, et al. (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188-196.
4. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, et al. (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 25: 888-896.
5. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or carcinoma. J Clin Endocrinol Metab 114: 3877-3885.
6. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, et al. (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92: 82-87.
7. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, et al. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88: 1433-41.
8. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, et al. (2006) European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154: 787-803.
9. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, et al. (1996) Human thyroglobulin reference material (CRM 457). 1st Part: Assessment of homogeneity, stability and immunoreactivity. Ann Biol, Clin 54: 337-342.
10. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, et al. (1996) Human thyroglobulin reference material (CRM 457). 2nd Part: Physicochemical characterization and certification. Ann Biol Clin 54: 343-348.
11. Wartofsky L (2002) Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid carcinoma without diagnostic (131)I scanning. J Clin Endocrinol Metab 87: 1486-1489.
12. Mazzaferri EL, Massoll N (2002) Management of papillary and follicular (differentiated) thyroid carcinoma: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 9: 227-247.
13. Schlumberger M, Ricard M, Pacini F (2000) Clinical use of recombinant human TSH in thyroid carcinuma patients. Eur J Endocrinol 143: 557-563.
14. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109-142.
15. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, et al. (2003) Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in die follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 148: 19-24.
16. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, et al. (2004) Follow-up of low risk patients with papillary thyroid carcinoma: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89: 3402-3407.
17. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, et al. (2003) Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97: 90-96.
18. Persona ACM, van den Ouweland JMW, Wilde J, Kema IP, Wolffenbuttel BHR, et al. (2006) Clinical utility of an automated immuno-chemiluminometric thyroglobulin assay in differentiated thyroid carcinoma. Clin Chem 52: 686-691.
19. Kessler A, Rappaport Y, Blank A, Marmor S, Weiss J, et al. (2003) Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma. J Clin Ultrasound 31: 21-25.
20. Ahuja AT, Ying M, Yuen HY, Metreweli C (2001) Power Doppler sonography of metastatic nodes from papillary carcinoma of the thyroid. Clin Radiol 56: 284-288.
21. Persoom ACM, Links TP, Wilde J, Sluiter WJ, Wolffenbuttel BHR, et al. (2006) Potential contributory value of thyroglobulin (Tg) recovery testing to quantitative Tg antibody measurement in determining serum Tg measurement interference in differentiated thyroid carcinoma. Clin Chem 52: 1196-1199.
22. Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, et al. (2005) Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 12: 273-280.
23. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijd JA, et al. (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 313-319.
24. Links TP, Jager PL, Persona ACM, Plukker JTM, Sluiter WJ (2006) Age is not a prognostic factor in differentiated thyroid carcinoma. J Clin Endocrinol Metab. Electronic Letter to the Editor 4 January 2006.
25. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297-306.
26. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, Lopresti JS (2005) Clinical Impact of Thyroglobulin (Tg) and Tg autoantibody Method Differences on the Management of patients with Differentiated Thyroid Carcinomas. J Clin Endocrinol Metab 90: 5566-5575.
27. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT (1999) Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9: 435-441.
28. Demers CM, Spencer CA, eds (2002) National Academy of Clinical Biochemistry Laboratory support for the diagnosis and monitoring of thyroid disease. Available at: http://www.nacb.org/lmpg/ thyroid_lmpg_pub.stm.
29. Rosario do PW, Borges MA, Fagundes TA, Franco AC, Purisch S (2005) Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 62: 121-125.
30. Zanotti-Fregonara P, Khoury A, Duran F, Keller I, Christin-Maitre S, et al. (2007) Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 34: 541-546.
31. Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, et al. (2002) Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin Chem 48: 1077-1083.
32. Lind P, Kohlfurst S (2006) Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 36: 194-205.
33. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, et al. (2006) Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 60: 409-413.
34. Hermanek P, Sabin LH (1992) Thyroid gland. In. Hermanek P, Sobin LH, eds (1992) TNM classification of malignant tumours, edn 4. Berlin. Springer-Verlag. pp 35-37.